BUSINESSSCMP WORLD
China’s Innovent Biologics signs US$10.5 billion Pfizer deal for 12 cancer drug trials
China’s Innovent Biologics has signed a $10.5 billion global collaboration with Pfizer to develop 12 cancer treatment programs. The deal includes an upfront payment of $650 million and potential milestone payments totaling up to $9.85 billion.
Mentioned
Related Signal
Adjacent reporting
- China’s Innovent Biologics signs US$10.5 billion Pfizer deal for 12 cancer drug trials
- China's Innovent Biologics signs drug deal with Pfizer worth up to $10.5bn
- STAT+: Bristol Myers Squibb partners with China’s Hengrui Pharma on a dozen drugs
- Portal CEO on Lilly Deal for Cancer Biotech CrossBridge
- Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion
- Chiesi Agrees to Buy KalVista Pharmaceuticals for $1.9 Billion